… ProQR Receives Fast Track Designation from FDA for QR-010 for … faster,” said Daniel de Boer, Chief Executive Officer of ProQR. “We are also looking forward to releasing data for the … in this study include sweat chloride, weight gain, CFQ-R Respiratory Symptom Score and lung function, measured by …
The trial, called WINGS, will evaluate the safety and efficacy of QR-313 in subjects with recessive dystrophic epidermolysis bullosa due to mutations in exon 73 of the COL7A1 gene.
Divestment of sepofarsen and ultevursen completed – Théa to continue development of sepofarsen and ultevursen for patients with LCA10 and Usher syndrome
LEIDEN, Netherlands & CAMBRIDGE, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced it will present new preclinical data for its proprietary Axiomer™ RNA editing